BridgeBio Oncology Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $2.40 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-01.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2025-08-01
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-06-30 was $738.70K, a 1223.65% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-03-31 was $1.66M, a 19867.06% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-06-30 was $55.81K.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-03-31 was $8.33K.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $104.71K, a 598.04% increase from fiscal 2023.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $15.00K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|
| 2025-06-30 | $738.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $2.40M 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $1.66M 10-Q · filed 2025-05-15 | ||
| 2024-12-31 | $104.71K 10-K · filed 2025-03-11 | ||
| 2024-06-30 | $55.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $64.14K 10-Q · filed 2025-08-01 | |
| 2024-03-31 | $8.33K 10-Q · filed 2025-05-15 | ||
| 2023-12-31 | $15.00K 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |